[go: up one dir, main page]

PL3237621T3 - Warianty ludzkiej alfa-galaktozydazy - Google Patents

Warianty ludzkiej alfa-galaktozydazy

Info

Publication number
PL3237621T3
PL3237621T3 PL15874075.3T PL15874075T PL3237621T3 PL 3237621 T3 PL3237621 T3 PL 3237621T3 PL 15874075 T PL15874075 T PL 15874075T PL 3237621 T3 PL3237621 T3 PL 3237621T3
Authority
PL
Poland
Prior art keywords
human alpha
galactosidase
variants
galactosidase variants
alpha
Prior art date
Application number
PL15874075.3T
Other languages
English (en)
Inventor
Nicholas J. Agard
Mathew G. Miller
Xiyun Zhang
Gjalt W. Huisman
Original Assignee
Codexis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codexis, Inc. filed Critical Codexis, Inc.
Publication of PL3237621T3 publication Critical patent/PL3237621T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL15874075.3T 2014-12-22 2015-12-02 Warianty ludzkiej alfa-galaktozydazy PL3237621T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095313P 2014-12-22 2014-12-22
US201562216452P 2015-09-10 2015-09-10
PCT/US2015/063329 WO2016105889A1 (en) 2014-12-22 2015-12-02 Human alpha-galactosidase variants

Publications (1)

Publication Number Publication Date
PL3237621T3 true PL3237621T3 (pl) 2023-10-30

Family

ID=56151383

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15874075.3T PL3237621T3 (pl) 2014-12-22 2015-12-02 Warianty ludzkiej alfa-galaktozydazy

Country Status (19)

Country Link
US (6) US20170360900A1 (pl)
EP (2) EP4234699A1 (pl)
JP (5) JP6650943B2 (pl)
KR (2) KR102702200B1 (pl)
AU (2) AU2015370125B2 (pl)
BR (1) BR112017013300A2 (pl)
CA (1) CA2970638A1 (pl)
DK (1) DK3237621T5 (pl)
ES (1) ES2944889T3 (pl)
FI (1) FI3237621T3 (pl)
HR (1) HRP20230468T1 (pl)
HU (1) HUE062016T2 (pl)
IL (1) IL252479B (pl)
LT (1) LT3237621T (pl)
PL (1) PL3237621T3 (pl)
PT (1) PT3237621T (pl)
RS (1) RS64574B1 (pl)
SI (1) SI3237621T1 (pl)
WO (1) WO2016105889A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3237621T (pt) 2014-12-22 2023-07-20 Codexis Inc Variantes da alfa-galactosidase humana
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
KR20180088919A (ko) 2015-12-24 2018-08-07 옥시레인 유케이 리미티드 인간 알파-n-아세틸갈락토사미니다아제 폴리펩티드
KR20210005167A (ko) 2018-04-27 2021-01-13 더 메디컬 컬리지 오브 위스콘신, 인크. 리소좀 축적병을 완화시키기 위한 렌티벡터-형질도입된 t-rapa 세포의 용도
US11708569B2 (en) 2018-08-29 2023-07-25 University Of Copenhagen Modified recombinant lysosomal alpha-galactosidase A and aspartylglucoaminidase having low mannose-6-phosphate and high sialic acid
AU2019403323A1 (en) * 2018-12-20 2021-07-01 Codexis, Inc. Human alpha-galactosidase variants
BR112022003705A2 (pt) 2019-08-30 2022-05-24 Codexis Inc Lipase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, composição farmacêutica para o tratamento de insuficiência pancreática, célula hospedeira, métodos para produzir uma lipase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, e, uso
WO2021055801A1 (en) * 2019-09-18 2021-03-25 The Medical College Of Wisconsin, Inc. Improved alpha-galactosidase protein for enzyme replacement therapy (ert) and methods of use
WO2021127457A1 (en) 2019-12-20 2021-06-24 Codexis, Inc. Engineered acid alpha-glucosidase variants
MX2022010663A (es) * 2020-02-28 2022-09-23 Codexis Inc Variantes de alfa-galactosidasa humana.

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US753653A (en) 1903-09-14 1904-03-01 American Car & Foundry Co Hopper-bottom car.
US6846968B1 (en) 1988-02-26 2005-01-25 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
JP3167729B2 (ja) 1994-06-30 2001-05-21 ノボ ノルディスク バイオテック，インコーポレイティド 無毒、非毒素原性、非病原性の発現系、並びにその中で利用するためのプロモーター及びターミネーター
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
KR100547402B1 (ko) * 1996-09-13 2006-02-01 트랜스케리오틱 쎄러피스, 인코포레이티드 α-갈락토시다아제 Ａ 결핍을 치료하는 방법
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
AU743305C (en) 1997-01-17 2006-03-30 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
JP2002522509A (ja) 1997-10-29 2002-07-23 ジェンザイム・コーポレイション リソソーム貯蔵疾患治療組成物および方法
KR20010032861A (ko) 1997-12-08 2001-04-25 캘리포니아 인스티튜트 오브 테크놀로지 폴리뉴클레오티드 및 폴리펩티드 서열을 형성하는 방법
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
AU3210100A (en) 1999-01-19 2000-08-01 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
EP1165775A2 (en) 1999-03-05 2002-01-02 Maxygen, Inc. Recombination of insertion modified nucleic acids
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
AU4964101A (en) 2000-03-30 2001-10-15 Maxygen Inc In silico cross-over site selection
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
SI2315145T1 (sl) 2002-03-01 2016-03-31 Codexis Mayflower Holdings, Llc Postopki, sistemi in programska oprema za identificiranje funkcionalnih biomolekul
JP4851687B2 (ja) 2002-03-09 2012-01-11 マキシジェン， インコーポレイテッド 定向進化のための交叉点の最適化
JP5570677B2 (ja) * 2002-04-25 2014-08-13 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド α−ガラクトシダーゼＡ欠損症の治療
WO2006099207A2 (en) 2005-03-10 2006-09-21 Diversa Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
EP2250594B1 (en) 2008-02-12 2017-04-19 Codexis, Inc. Method of generating an optimized, diverse population of variants
HUE034642T2 (en) 2008-02-12 2018-02-28 Codexis Inc A method for selecting an optimized diverse population of variants
EP2285958B1 (en) 2008-06-13 2016-03-09 Codexis, Inc. Method of synthesizing polynucleotide variants
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
US9194011B2 (en) * 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
WO2013003290A1 (en) 2011-06-28 2013-01-03 Codexis, Inc. Protein variant generation by region shuffling
US8876066B1 (en) 2009-12-17 2014-11-04 Progressive Fastening, Inc. Hanger with bolt closures
US20130039898A1 (en) 2010-02-04 2013-02-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
DK2865751T3 (en) 2010-03-02 2017-01-09 Protalix Ltd Stabilized alpha-galactosidase and uses thereof
EP4458350A3 (en) 2011-06-08 2025-01-22 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
JP5431428B2 (ja) 2011-09-02 2014-03-05 京楽産業．株式会社 遊技機
WO2013138339A1 (en) 2012-03-15 2013-09-19 Codexis, Inc. Gene shuffling methods
EP2839001B1 (en) * 2012-04-18 2017-09-06 VIB vzw Means and methods for generating improved proteins
CA2899859C (en) 2013-01-31 2022-08-16 Codexis, Inc. Methods, systems, and software for identifying biomolecules with interacting components
DK3049979T3 (da) 2013-09-27 2020-02-17 Codexis Inc Struktur-baseret prædiktiv konstruktion
KR102342205B1 (ko) 2013-09-27 2021-12-21 코덱시스, 인코포레이티드 효소 변이체의 자동화 스크리닝
US9909113B2 (en) 2014-06-12 2018-03-06 Research Foundation Of The City University Of New York Purification of recombinant alpha galactosidase A
PT3237621T (pt) 2014-12-22 2023-07-20 Codexis Inc Variantes da alfa-galactosidase humana
US20170051267A1 (en) 2015-08-20 2017-02-23 Research Foundation Of The City University Of New York Novel alpha-galactosidase a derivatives
JP7114485B2 (ja) 2016-05-18 2022-08-08 モデルナティエックス インコーポレイテッド ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド
EP3568152A1 (en) 2017-01-10 2019-11-20 Amicus Therapeutics, Inc. Recombinant alpha-galactosidase a for treatment of fabry disease
US20210009984A1 (en) 2017-12-22 2021-01-14 Hanmi Pharm. Co., Ltd. Therapeutic enzyme fusion protein having a novel structure and use thereof
AU2019403323A1 (en) 2018-12-20 2021-07-01 Codexis, Inc. Human alpha-galactosidase variants
JP2021021820A (ja) 2019-07-26 2021-02-18 富士ゼロックス株式会社 画像形成装置及びプログラム
WO2021026447A1 (en) 2019-08-07 2021-02-11 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
MX2022010663A (es) 2020-02-28 2022-09-23 Codexis Inc Variantes de alfa-galactosidasa humana.
AU2023331251A1 (en) 2022-08-25 2025-02-27 Takeda Pharmaceutical Company Limited Composition for use in the treatment of fabry disease

Also Published As

Publication number Publication date
EP3237621A4 (en) 2018-12-05
JP6650943B2 (ja) 2020-02-19
IL252479A0 (en) 2017-07-31
AU2015370125A1 (en) 2017-06-22
ES2944889T3 (es) 2023-06-26
EP4234699A1 (en) 2023-08-30
RS64574B1 (sr) 2023-10-31
US20200360490A1 (en) 2020-11-19
US20250041388A1 (en) 2025-02-06
SI3237621T1 (sl) 2023-11-30
FI3237621T3 (fi) 2023-06-01
LT3237621T (lt) 2023-09-25
BR112017013300A2 (pt) 2018-02-27
HRP20230468T1 (hr) 2023-11-10
JP2018500907A (ja) 2018-01-18
US11497798B2 (en) 2022-11-15
US12257291B2 (en) 2025-03-25
PT3237621T (pt) 2023-07-20
DK3237621T5 (da) 2024-10-14
EP3237621A1 (en) 2017-11-01
JP2019076110A (ja) 2019-05-23
NZ732171A (en) 2021-01-29
AU2022202939B2 (en) 2025-03-06
JP2022097653A (ja) 2022-06-30
KR20170093976A (ko) 2017-08-16
US20170360900A1 (en) 2017-12-21
US20200360489A1 (en) 2020-11-19
KR102438885B1 (ko) 2022-09-01
KR20220123342A (ko) 2022-09-06
CA2970638A1 (en) 2016-06-30
WO2016105889A1 (en) 2016-06-30
JP2024150549A (ja) 2024-10-23
US12263207B2 (en) 2025-04-01
US20200405826A1 (en) 2020-12-31
US10973888B2 (en) 2021-04-13
AU2015370125B2 (en) 2022-02-03
IL252479B (en) 2021-03-25
KR102702200B1 (ko) 2024-09-02
AU2022202939A1 (en) 2022-05-26
US20210244804A1 (en) 2021-08-12
DK3237621T3 (da) 2023-06-19
HUE062016T2 (hu) 2023-09-28
JP2021003129A (ja) 2021-01-14
US11278600B2 (en) 2022-03-22
EP3237621B1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
SI3132034T1 (sl) Zdravstveni pripomočki
IL250387A0 (en) combined treatment
IL252479A0 (en) Variants of human alpha-galactosidase
IL250990A0 (en) Materials for human care
GB201410816D0 (en) Therapeutic agents
GB201405033D0 (en) Combination therapy
SG11201601030VA (en) Massager
GB201410216D0 (en) Therapeutic
GB201410817D0 (en) Therapeutic agents
GB201410815D0 (en) Therapeutic agents
GB201510637D0 (en) Therapeutic
IL249240A0 (en) Combined treatment
GB201411027D0 (en) Treatment
HUE038273T2 (hu) Koporsó
GB201412411D0 (en) Treatment
GB201418508D0 (en) Therapeutic
GB201413719D0 (en) Therapeutic
GB201410832D0 (en) Therapeutic
GB201410334D0 (en) Therapeutic
GB201406674D0 (en) Therapeutic
GB201421879D0 (en) Therapeutic agents
GB201421715D0 (en) Therapeutic agents
GB201409241D0 (en) Therapeutic agents
GB201409244D0 (en) Therapeutic agents
AU2014324V (en) MALOF002 Acmena smithii